GLP-1 and Fasting Insulin: Resistance Tracking

Fasting insulin is one of the most revealing metabolic markers available, yet it is often overlooked in routine blood work. Elevated fasting insulin indicates insulin resistance, the metabolic dysfunction that underlies obesity, type 2 diabetes, and cardiovascular disease. GLP-1 medications dramatically improve insulin sensitivity, and tracking fasting insulin shows this improvement in real numbers.

What Fasting Insulin Tells You

Fasting insulin measures how much insulin your pancreas produces to maintain normal blood sugar after an overnight fast. Optimal and concerning ranges:

• Optimal: 2-6 uIU/mL
• Normal range: 2-25 uIU/mL (lab-dependent)
• Insulin resistant: Above 10-15 uIU/mL (even within "normal" range)
• Significantly resistant: Above 25 uIU/mL

The key insight: fasting insulin rises long before blood sugar becomes abnormal. You can have a normal fasting glucose and A1C while having elevated fasting insulin, meaning your body is working harder and harder to maintain normal sugar levels. This is early insulin resistance, and it is the ideal time to intervene.

HOMA-IR: The Resistance Score

HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) combines fasting insulin and fasting glucose to produce a single insulin resistance score:

HOMA-IR = (Fasting Insulin x Fasting Glucose) / 405

• Optimal: Below 1.0
• Normal: Below 1.9
• Early insulin resistance: 1.9-2.9
• Significant insulin resistance: 3.0 and above

How GLP-1 Improves Insulin Sensitivity

• Direct pancreatic effects: GLP-1 improves insulin secretion patterns, making them more efficient and glucose-responsive
• Visceral fat reduction: Visceral fat is the primary driver of insulin resistance; GLP-1 medications preferentially reduce it
• Liver fat reduction: Hepatic steatosis impairs insulin signaling; reducing liver fat restores it
• Muscle insulin sensitivity: Weight loss and metabolic improvement increase glucose uptake by muscles
• Inflammation reduction: Chronic inflammation impairs insulin signaling; reducing it improves sensitivity

Expected Improvements

Patients on GLP-1 medications typically see:

• Fasting insulin drops of 30-50% over 6-12 months
• HOMA-IR improvements of 40-60%
• Many patients move from insulin resistant to normal range
• Improvements often exceed what weight loss alone would predict

Monitoring Schedule

• Baseline: Fasting insulin and fasting glucose before treatment
• 3-6 months: First follow-up to assess improvement
• 12 months: Comprehensive metabolic reassessment
• Annually: Ongoing monitoring

Getting Started

If you suspect insulin resistance or want to track your metabolic improvement during GLP-1 treatment, visit Trimi's treatment options page. Compounded semaglutide is $99/month and tirzepatide is $125/month.

Frequently Asked Questions

Is fasting insulin included in standard blood work?

No, fasting insulin is not part of standard metabolic panels. You typically need to request it specifically. It is an inexpensive add-on test that provides valuable metabolic information.

Can GLP-1 reverse insulin resistance?

Yes. GLP-1 medications, combined with weight loss, can reverse insulin resistance in many patients. Fasting insulin and HOMA-IR often normalize with treatment, which reduces the risk of progressing to type 2 diabetes.

Which GLP-1 is best for insulin resistance?

Both semaglutide and tirzepatide effectively improve insulin sensitivity. Tirzepatide may have a slight advantage due to GIP receptor activation's additional metabolic effects. Both are available through Trimi at $99/month and $125/month respectively.

How long until insulin resistance improves?

Improvement begins within weeks of starting GLP-1 medication, but measurable changes in fasting insulin typically take 3-6 months. Maximum improvement correlates with peak weight loss at 12-18 months.